NASDAQ: KZIA - Kazia Therapeutics Limited

Lønnsomhet i seks måneder: +192.71%
Utbytte: 0.00%
Sektor: Healthcare

Kampanjeplan Kazia Therapeutics Limited

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet Kazia Therapeutics Limited

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.

Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 1999-01-06
ISIN US48669G1058
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета aud
Див.доход ао 53.19
Дивиденд ао 4.09
Сайт https://www.kaziatherapeutics.com
Цена ао 0.96
Prisendring per dag: 0% (0.9952)
Prisendring per uke: +4.79% (0.9497)
Prisendring per måned: +5.91% (0.9397)
Prisendring over 3 måneder: -70.11% (3.33)
Prisendring over seks måneder: +192.71% (0.34)
Prisendring per år: +290.43% (0.2549)
Prisendring over 3 år: -83.55% (6.05)
Prisendring over 5 år: -75.27% (4.0238)
Prisendring over 10 år: 0% (0.9952)
Prisendring siden begynnelsen av året: -66.49% (2.97)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 61225.34 1
P/BV 2.82 6
P/E 0 0
EV/EBITDA -1.37 0
Total: 4.38

Effektivitet

Navn Betydning Karakter
ROA, % -107.82 0
ROE, % -2633.62 0
Total: 1.67

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0.5 5
Total: 2.14

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.0237 10
Total: 10

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 217430.63 10
Lønnsomhet Ebitda, % 133.95 10
Lønnsomhet EPS, % 835.57 10
Total: 8.4
Flere detaljer

Institusjoner Volum Dele, %
Armistice Capital, LLC 2475555 10.47
Platinum Investment Management Ltd 1821887 7.71
Morgan Stanley 201550 0.85
Bank of Montreal/Can/ 140166 0.59
HSBC Holdings PLC 100194 0.42
TWO SIGMA SECURITIES, LLC 58423 0.25
XTX Topco Ltd 19436 0.08
Acadian Asset Management. LLC 18682 0.08
Citadel Advisors Llc 12809 0.05
BNP Paribas Financial Markets 12700 0.05



Veileder Stillingstittel Betaling Fødselsår
Ms. Anna Sandham Company Secretary N/A
Dr. John Edwin Friend II, M.D. CEO, MD & Director 731.09k 1970 (55 år)
Ms. Gabrielle Heaton BBUS (ACC), CPA Principal Accounting Officer, VP of Finance & Administration and Principal Financial Officer 178.56k

Adresse: Australia, Sydney, Three International Towers - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.kaziatherapeutics.com